Answer
Thrombocytopenia and anaemia have been reported post-marketing in infants born to women exposed to natalizumab during pregnancy; monitoring neonatal platelet counts, haemoglobin and haematocrit is recommended.
Sources for this answer
- TYSABRI 300 mg concentrate for solution for infusionBiogen Idec Ltd · emc · SmPC §4.6 Fertility, pregnancy and lactation · Version 43Document updated
Sources checked